Rocket Pharmaceuticals, Inc. (RCKT): who owns it and who trades it
As of Nov 16, 2026, RCKT insiders reported 27 open-market sales worth $1M and 1 purchase worth $34.4K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Martin Wilson (General Counsel), with $462K. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Rocket Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RCKT
179 funds and institutions reported RCKT shares worth $344M at the end of Q2 2026, about 92% of the company. The largest holder is Rtw Investments, LP with 16.2%.
Funds and institutions (13F) 92%Everyone else 8%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Rtw Investments, LP | 17.69M | 16.20% | $60.5M | No change |
| BlackRock, Inc. | 9.92M | 9.09% | $33.9M | +27% |
| Vanguard Portfolio Management LLC | 5.81M | 5.32% | $19.9M | +24% |
| Citigroup Inc | 4.87M | 4.46% | $16.6M | -5% |
| Marshall Wace, LLP | 4.03M | 3.69% | $13.8M | +33% |
| Millennium Management LLC | 4.00M | 3.66% | $13.7M | +28% |
| Newtyn Management, LLC | 4.00M | 3.66% | $13.7M | +26% |
| Maverick Capital Ltd | 3.92M | 3.59% | $13.4M | +10% |
| Vanguard Capital Management LLC | 3.78M | 3.47% | $12.9M | +0% |
| AQR Capital Management LLC | 3.39M | 3.10% | $11.6M | +10% |
| Goldman Sachs Group Inc | 2.83M | 2.59% | $9.7M | +65% |
| Monaco Asset Management SAM | 2.48M | 2.27% | $8.5M | +21% |
| Geode Capital Management, LLC | 2.37M | 2.17% | $8.1M | +8% |
| Federated Hermes, Inc. | 2.30M | 2.11% | $7.9M | +125% |
| JPMorgan Chase & Co | 1.99M | 1.82% | $6.7M | – |
| Jacobs Levy Equity Management, Inc | 1.97M | 1.81% | $6.8M | +374% |
| State Street Corp | 1.82M | 1.67% | $6.2M | -59% |
| Dimensional Fund Advisors LP | 1.13M | 1.03% | $3.8M | +290% |
| Morgan Stanley | 1.06M | 0.97% | $3.6M | -47% |
| Opaleye Management Inc. | 1.00M | 0.92% | $3.4M | +5% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RCKT insiders reported $34.4K of open-market purchases and $1M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Sarbani Chaudhuri | See Remarks | Sale | 4,872 | $2.33 | $11.3K | Form 4 |
| Nov 5, 2026 | Martin Wilson | General Counsel | Sale | 53,389 | $2.39 | $128K | Form 4 |
| Sep 11, 2026 | Martin Wilson | General Counsel | Sale | 75,364 | $3.40 | $256K | Form 4 |
| Aug 18, 2026 | Martin Wilson | General Counsel | Sale | 631 | $3.38 | $2.1K | Form 4 |
| Aug 18, 2026 | Gaurav Shah | CEO | Sale | 2,293 | $3.38 | $7.8K | Form 4 |
| Aug 13, 2026 | Gaurav Shah | CEO | Sale | 2,837 | $3.38 | $9.6K | Form 4 |
| Aug 13, 2026 | Martin Wilson | General Counsel | Sale | 3,493 | $3.38 | $11.8K | Form 4 |
| Aug 11, 2026 | Christopher James Stevens | Chief Operating Officer | Sale | 36,658 | $3.50 | $128K | Form 4 |
| Aug 11, 2026 | Sarbani Chaudhuri | See Remarks | Sale | 4,701 | $3.50 | $16.5K | Form 4 |
| May 21, 2026 | Gaurav Shah | CEO | Sale | 55,684 | $3.09 | $172K | Form 4 |
| May 19, 2026 | Gaurav Shah | CEO | Sale | 2,409 | $3.01 | $7.3K | Form 4 |
| May 19, 2026 | Martin Wilson | General Counsel | Sale | 662 | $3.01 | $2K | Form 4 |
| May 19, 2026 | John Militello | See Remarks | Sale | 384 | $3.01 | $1.2K | Form 4 |
| May 13, 2026 | Martin Wilson | General Counsel | Sale | 3,361 | $3.61 | $12.1K | Form 4 |
| May 13, 2026 | Gaurav Shah | CEO | Sale | 2,728 | $3.61 | $9.8K | Form 4 |
| May 13, 2026 | John Militello | See Remarks | Sale | 855 | $3.61 | $3.1K | Form 4 |
| May 7, 2026 | Sarbani Chaudhuri | See Remarks | Sale | 17,650 | $3.84 | $67.8K | Form 4 |
| Feb 18, 2026 | John Militello | See Remarks | Sale | 1,157 | $3.34 | $3.9K | Form 4 |
| Feb 18, 2026 | Gaurav Shah | CEO | Sale | 5,990 | $3.34 | $20K | Form 4 |
| Feb 18, 2026 | Martin Wilson | General Counsel | Sale | 1,376 | $3.34 | $4.6K | Form 4 |
| Feb 13, 2026 | Martin Wilson | General Counsel | Sale | 12,253 | $3.31 | $40.6K | Form 4 |
| Feb 13, 2026 | John Militello | See Remarks | Sale | 3,726 | $3.31 | $12.3K | Form 4 |
| Feb 13, 2026 | Gaurav Shah | CEO | Sale | 12,279 | $3.31 | $40.6K | Form 4 |
| Jan 2, 2026 | Elisabeth Bjork | Director | Purchase | 10,000 | $3.44 | $34.4K | Form 4 |
| Nov 18, 2025 | John Militello | See Remarks | Sale | 1,086 | $2.98 | $3.2K | Form 4 |
| Nov 18, 2025 | Jonathan David Schwartz | See Remarks | Sale | 2,545 | $2.98 | $7.6K | Form 4 |
| Nov 18, 2025 | Gaurav Shah | CEO | Sale | 6,276 | $2.98 | $18.7K | Form 4 |
| Nov 18, 2025 | Martin Wilson | General Counsel | Sale | 1,646 | $2.98 | $4.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Martin Wilson | General Counsel | – | $462K | Nov 5, 2026 |
| Gaurav Shah | CEO, Director | – | $286K | Aug 18, 2026 |
| Christopher James Stevens | Chief Operating Officer | – | $128K | Aug 11, 2026 |
| Sarbani Chaudhuri | See Remarks | – | $95.6K | Nov 9, 2026 |
| Elisabeth Bjork | Director | $34.4K | – | Jan 2, 2026 |
| John Militello | See Remarks | – | $23.7K | May 19, 2026 |
| Jonathan David Schwartz | See Remarks | – | $7.6K | Nov 18, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RCKT short interest
High short interest. 14.8% of RCKT shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 22%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 16.24M RCKT shares were sold short, 14.8% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 1.79M shares, buying them all back would take about 9.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 16.24M | 14.80% | -0% | 1.79M | 9.1 |
| Oct 15, 2026 | 16.28M | 14.83% | +8% | 2.44M | 6.7 |
| Sep 30, 2026 | 15.05M | 13.71% | +1% | 2.17M | 6.9 |
| Sep 15, 2026 | 14.85M | 13.53% | +1% | 1.34M | 11.1 |
| Aug 31, 2026 | 14.71M | 13.40% | +2% | 1.50M | 9.8 |
| Aug 14, 2026 | 14.39M | 13.11% | -7% | 1.68M | 8.6 |
| Jul 31, 2026 | 15.50M | 14.12% | -6% | 1.30M | 11.9 |
| Jul 15, 2026 | 16.57M | 15.18% | -9% | 2.44M | 6.8 |
| Jun 30, 2026 | 18.16M | 16.63% | -17% | 3.65M | 5.0 |
| Jun 15, 2026 | 21.90M | 20.06% | -2% | 2.62M | 8.3 |
| May 29, 2026 | 22.45M | 20.56% | +7% | 2.36M | 9.5 |
| May 15, 2026 | 20.95M | 19.19% | -3% | 2.08M | 10.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Rocket Pharmaceuticals company events
Rocket Pharmaceuticals filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 6, 2026.
- Oct 6, 2026AgreementRocket Pharmaceuticals, Inc., together with its subsidiaries Spacecraft Seven, LLC and Zebrafish Merger Sub II, LLC (together with the Company, “Borrower”), entered into a Loan and Security Agreement with the several banks and other financial institutions or entities from time to time party thereto… Filing
- Sep 15, 2026AnnouncementShared information with investors. Filing
- Aug 27, 2026LeadershipThe Board of Directors of Rocket Pharmaceuticals, Inc. adopted the Rocket Pharmaceuticals, Inc. Severance and Change in Control Program. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Aug 3, 2026AnnouncementShared information with investors. Filing
- Jun 30, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. Filing
- Jun 12, 2026DealRocket Pharmaceuticals, Inc. completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company. Filing
- May 21, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 28, 2026AgreementRocket Pharmaceuticals, Inc. entered into a definitive asset purchase agreement pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher. Filing
- Mar 27, 2026AnnouncementShared information with investors. Filing
- Mar 10, 2026AgreementRocket Pharmaceuticals, Inc. entered into a sales agreement with Cantor Fitzgerald & Co., with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Rocket Pharmaceuticals financials
Famous investors that hold RCKT
6 of the 50 well-known investors we track reported holding RCKT in their latest 13F filing. The largest position is Israel Englander's, worth $12.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 4.82M | $12.7M | 0.0% | +21% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 3.84M | $10.1M | 0.1% | -2% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 928,731 | $2.4M | 0.0% | +17% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 516,662 | $1.4M | 0.0% | -23% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 365,695 | $962K | 0.0% | +414% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 50,493 | $133K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RCKT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 30, 2026 | Vanguard Portfolio Management | 13G/A | 1.3% |
| Oct 30, 2026 | Vanguard Portfolio Management | 13G/A | 1.3% |
Questions about Rocket Pharmaceuticals, Inc. (RCKT) stock
Who owns the most RCKT stock?
The largest reported owner of Rocket Pharmaceuticals, Inc. (RCKT) is Rtw Investments, LP, with 16.2% of the company. In total, 179 funds and institutions reported holding RCKT at the end of Q2 2026, together about 92% of the shares. See the largest owners.
Are RCKT insiders buying or selling?
In the last 12 months, RCKT insiders reported 1 open-market purchase worth $34.4K and 27 sales worth $1M. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in RCKT?
As of Oct 30, 2026, 16.24M RCKT shares were sold short, 14.8% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 1.79M shares, buying them all back would take about 9.1 trading days (days to cover). See the history.
Which famous investors hold RCKT?
6 of the 50 well-known investors we track reported RCKT in their latest 13F filing, including Israel Englander, Lee Ainslie, Jim Simons. The largest position is worth $12.7M. See all holders.
Executive pay
Rocket Pharmaceuticals's chief executive was paid a total of $3.5M for the year ended Dec 31, 2025, down 49% from $6.8M the year before. In the last 12 months, Rocket Pharmaceuticals's executives and directors bought $34.4K of stock on the open market and sold $1M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.